BIOMAT Database Logo BIOMAT Database Logo

Characterization of prostaglandin (PG)-binding sites expressed on human basophils. Evidence for a prostaglandin E1, I2, and a D2 receptor. 1992

I Virgolini, and S Li, and C Sillaber, and O Majdic, and H Sinzinger, and K Lechner, and P Bettelheim, and P Valent
Department of Nuclear Medicine, University of Vienna, Austria.

Recent data suggest that prostaglandins (PGs) are involved in the regulation of basophil activation. The aim of this study was to characterize the basophil PG-binding sites by means of radioreceptor assays using 3H-labeled PGs. Scatchard analysis for pure (greater than 95%) chronic myeloid leukemia (CML) basophils revealed two classes of PGE1-binding sites differing in their affinity for the natural ligand (Bmax1 = 217 +/- 65 fmol/10(8) cells; Kd1 = 0.5 +/- 0.2 nM; Bmax2 = 2462 +/- 381 fmol/10(8) cells; Kd2 = 47 +/- 20 nM; IC50 = PGE1 less than PGI2 less than PGD2 less than PGE2 less than PGF2 alpha) as well as two classes of PGI2 (iloprost)-binding sites (Bmax1 = 324 +/- 145 fmol/10(8) cells; Kd1 = 0.5 +/- 0.3 nM; Bmax2 = 2541 +/- 381; Kd2 = 27 +/- 6 nM; IC50 = PGI2 less than PGE1 less than PGD2 less than PGE2 less than PGF2 alpha. In addition, CML basophils exhibited a single class of PGD2-binding sites (Bmax = 378 +/- 98 fmol/10(8) cells; Kd = 13 +/- 4 nM; IC50: PGD2 less than PGI2 less than PGE1 less than PGE2 less than PGF2 alpha). In contrast, we were unable to detect specific saturable PGE2-binding sites. Primary and immortalized (KU812) CML basophils revealed an identical pattern of PG receptor expression. Basophils (KU812) expressed significantly (p less than 0.001) lower number of PGE1 (PGI2)-binding sites (Bmax1: 9% (20%) of control; Bmax2: 36% (50%) of control) when cultured with recombinant interleukin 3 (rhIL-3), a basophil-activating cytokine, whereas rhIL-2 had no effect on PG receptor expression. Functional significance of binding of PGs to basophils was provided by the demonstration of a dose-dependent increase in cellular cAMP upon agonist activation, with PGE1 (ED50 = 1.7 +/- 1.1 nM) and PGI2 (ED50 = 2.8 +/- 2.3 nM) being the most potent compounds. These findings suggest that human basophils express specific receptors for PGE1, PGI2 as well as for PGD2.

UI MeSH Term Description Entries
D007377 Interleukin-3 A multilineage cell growth factor secreted by LYMPHOCYTES; EPITHELIAL CELLS; and ASTROCYTES which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. Burst-Promoting Factor, Erythrocyte,Colony-Stimulating Factor 2 Alpha,Colony-Stimulating Factor, Mast-Cell,Colony-Stimulating Factor, Multipotential,Erythrocyte Burst-Promoting Factor,IL-3,Mast-Cell Colony-Stimulating Factor,Multipotential Colony-Stimulating Factor,P-Cell Stimulating Factor,Eosinophil-Mast Cell Growth-Factor,Hematopoietin-2,Burst Promoting Factor, Erythrocyte,Colony Stimulating Factor, Mast Cell,Colony Stimulating Factor, Multipotential,Eosinophil Mast Cell Growth Factor,Erythrocyte Burst Promoting Factor,Hematopoietin 2,Interleukin 3,Multipotential Colony Stimulating Factor,P Cell Stimulating Factor
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D011982 Receptors, Prostaglandin Cell surface receptors that bind prostaglandins with high affinity and trigger intracellular changes which influence the behavior of cells. Prostaglandin receptor subtypes have been tentatively named according to their relative affinities for the endogenous prostaglandins. They include those which prefer prostaglandin D2 (DP receptors), prostaglandin E2 (EP1, EP2, and EP3 receptors), prostaglandin F2-alpha (FP receptors), and prostacyclin (IP receptors). Prostaglandin Receptors,Prostaglandin Receptor,Receptor, Prostaglandin,Receptors, Prostaglandins,Prostaglandins Receptors
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

I Virgolini, and S Li, and C Sillaber, and O Majdic, and H Sinzinger, and K Lechner, and P Bettelheim, and P Valent
Evidence for distinct prostaglandin I2 and D2 receptors in human platelets.
July 1979, The Journal of pharmacology and experimental therapeutics,
I Virgolini, and S Li, and C Sillaber, and O Majdic, and H Sinzinger, and K Lechner, and P Bettelheim, and P Valent
Specific binding sites for prostaglandin D2 on human platelets.
September 1979, Biochemical and biophysical research communications,
I Virgolini, and S Li, and C Sillaber, and O Majdic, and H Sinzinger, and K Lechner, and P Bettelheim, and P Valent
The antagonism of prostaglandins I2, E1 and D2 by prostaglandin E2 in human platelets.
January 1981, Thrombosis research,
I Virgolini, and S Li, and C Sillaber, and O Majdic, and H Sinzinger, and K Lechner, and P Bettelheim, and P Valent
Agonist and antagonist effects of 15R-prostaglandin (PG) D2 and 11-methylene-PGD2 on human eosinophils and basophils.
January 2007, The Journal of pharmacology and experimental therapeutics,
I Virgolini, and S Li, and C Sillaber, and O Majdic, and H Sinzinger, and K Lechner, and P Bettelheim, and P Valent
[Prostaglandin I2 (PG I2; prostacyclin) synthesis by human gastric mucosa (author's transl)].
November 1979, Wiener klinische Wochenschrift,
I Virgolini, and S Li, and C Sillaber, and O Majdic, and H Sinzinger, and K Lechner, and P Bettelheim, and P Valent
Prostaglandin E1 and prostaglandin I2 modulation of superoxide production by human neutrophils.
June 1983, Biochemical and biophysical research communications,
I Virgolini, and S Li, and C Sillaber, and O Majdic, and H Sinzinger, and K Lechner, and P Bettelheim, and P Valent
Decrease of prostaglandin I2 binding sites in thyroid cancer.
November 1988, British journal of cancer,
I Virgolini, and S Li, and C Sillaber, and O Majdic, and H Sinzinger, and K Lechner, and P Bettelheim, and P Valent
Identification of platelet receptors for prostaglandin I2 and D2.
April 1979, The Journal of biological chemistry,
I Virgolini, and S Li, and C Sillaber, and O Majdic, and H Sinzinger, and K Lechner, and P Bettelheim, and P Valent
Impaired prostaglandin E1/I2 receptor activity of human blood platelets in acute ischemic heart disease.
April 1990, Circulation research,
I Virgolini, and S Li, and C Sillaber, and O Majdic, and H Sinzinger, and K Lechner, and P Bettelheim, and P Valent
Characterization of the promoter of human CRTh2, a prostaglandin D2 receptor.
November 2007, Biochemical and biophysical research communications,
Copied contents to your clipboard!